Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies - PubMed
5 hours ago
- #long-term safety
- #axial spondyloarthritis
- #bimekizumab
- Bimekizumab demonstrated sustained safety and efficacy over 3 years across the axial spondyloarthritis spectrum.
- No new safety signals were observed; fungal infections (mostly Candida) were common but generally mild or moderate.
- Efficacy outcomes, including ASDAS low disease activity and MRI inflammation control, were maintained through Week 164.